Applications including "United States Pharmacopoeia"

GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

GC InertSearch InertCap 624MS
LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC InertSearch InertSustain AQ-C18
LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustainC18
LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC InertSearch InertCore C8
LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LC InertSearch InertSustain C8
LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC InertSearch Inertsil Hybrid-C18
LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC InertSearch InertSustain C8
LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC InertSearch InertSustain C8
LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC InertSearch InertSustainSwift C18
LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC InertSearch InertSustainSwift C18
LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC InertSearch InertSustain C18
LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC InertSearch InertSustain NH2
LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC InertSearch InertSustain C18
LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC InertSearch Inertsil Hybrid-C18
LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC InertSearch InertSustainSwift C18
LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC InertSearch InertSustain C18
LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC InertSearch InertSustain C18
LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC InertSearch Inertsil WP300 C18
LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC InertSearch InertSustain C18
LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC InertSearch InertSustain C8
LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC InertSearch InertSustain C8
LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC InertSearch InertSustain AQ-C18
LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC InertSearch Inertsil WP300 C18
LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC InertSearch InertSustain C18
LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC InertSearch InertSustain C8
LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC InertSearch InertSustain C18
LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC InertSearch InertSustainSwift C8
LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC InertSearch InertSustainSwift C8
LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC InertSearch InertSustain C18
LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC InertSearch InertSustain C18
LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC InertSearch InertSustain C8
LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC InertSearch InertSustain C8
LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC InertSearch InertSustain C18
LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC InertSearch InertSustain C18
LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC InertSearch InertSustain C18
LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC InertSearch InertSustain C18
LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC InertSearch Inertsil ODS-HL
LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC InertSearch InertSustainSwift C18
LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC InertSearch Inertsil NH2
LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch Inertsil ODS-3
LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch InertSustain C18
LB991 - Analysis of Progestrone and Methyltestrone -

LC InertSearch Inertsil WP300 C18
LB985 - Analysis of Sumatriptan -

LC InertSearch Inertsil ODS-3
LB984 - Analysis of Sumatriptan -

LC InertSearch InertSustain AQ-C18
LB982 - Analysis of Ofloxacin -

LC InertSearch InertSustain C18
LB981 - Analysis of Ofloxacin -

LC InertSearch Inertsil WP300 C18
LB980 - Analysis of Desloratadine -

LC InertSearch InertSustain AQ-C18
LB961 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LB960 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LT147 - D-Mannitol Analysis Under USP Method -

LC Technical Note InertSphere Sugar-2 HAMILTON HC-75（Ca2+）
LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

LC Technical Note
GT093 - Quantitative Test for Hydroxypropylcellulose with Reference to the Japanese Pharmacopoeia, 17th Edition -

GC Technical Note InertCap 1 InertCap Series
GT086 - Purity Test and Fatty Acid Content Ratio Test of Polysorbate 80 - Supplement II to the Japanese Pharmacopoeia, 16th Edition -

GC Technical Note InertCap Pure-WAX InertCap 5

Applications including "United States Pharmacopoeia"

GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LB991 - Analysis of Progestrone and Methyltestrone -

LB985 - Analysis of Sumatriptan -

LB984 - Analysis of Sumatriptan -

LB982 - Analysis of Ofloxacin -

LB981 - Analysis of Ofloxacin -

LB980 - Analysis of Desloratadine -

LB961 - Analysis of Lidocaine -

LB960 - Analysis of Lidocaine -

LT147 - D-Mannitol Analysis Under USP Method -

LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

GT093 - Quantitative Test for Hydroxypropylcellulose with Reference to the Japanese Pharmacopoeia, 17th Edition -

GT086 - Purity Test and Fatty Acid Content Ratio Test of Polysorbate 80 - Supplement II to the Japanese Pharmacopoeia, 16th Edition -

Application Search